• Sign In
  • Sign Out
  • My Account
Subscribe
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
  • Special reports
Clarivate
  • Data Snapshots
  • BioWorld
  • BioWorld MedTech
  • Infographics: Dynamic digital data analysis
  • Special reports
  • Infographics: Dynamic digital data analysis
  • Trump administration impacts
  • Biopharma M&A scorecard
  • BioWorld 2024 review
  • BioWorld MedTech 2024 review
  • BioWorld Science 2024 review
  • Women's health
  • China's GLP-1 landscape
  • PFA re-energizes afib market
  • China CAR T
  • Alzheimer's disease
  • Israel
  • Rise of obesity
  • Radiopharmaceuticals
  • Biosimilars
  • Aging
  • IVDs on the rise
  • Coronavirus
  • Artificial intelligence

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
Home » Newsletters » BioWorld

BioWorld

Sep. 24, 2014

View Archived Issues

IRS tries to close door on the pharma hunt for foreign addresses and less tax

U.S. drugmakers' quest for tax-friendly foreign addresses could get waylaid by the Treasury Department's efforts to end corporate inversions. The inversions, which involve U.S.-based multinationals moving their tax residence overseas to take advantage of more favorable corporate tax rates, have become a popular theme in the pharmaceutical industry over the past few years, with several companies acquiring addresses in Ireland. Read More

GSK's China verdict best possible outcome; blacklisting still worry

SHANGHAI – After a 15-month corruption investigation, the verdict for Glaxosmithkline plc in China has been guilty as charged, surprising few industry insiders. It is routine for the government to come out on top in such high-profile cases, while most readily admit there are no saints in China's downstream pharmaceutical business. Read More

DBV stock up on peanut allergy data; firm files for offering on Nasdaq

DUBLIN – Shares in DBV Technologies SA gained more than 20 percent Tuesday on positive news from a phase IIb trial of the company's Viaskin Peanut allergy treatment. Read More

Autoimmune therapy: Novo's effort quashed, J&J sees hope in game

BOSTON – With autoimmune/anti-inflammatory agents abounding, biotech firms may be hard pressed to develop competitive drugs, but the market still is worth going after and big pharma is willing to pay for therapies that can help the wide sector of nonresponders. Read More

Report: Accelerated pathways not speeding drugs to market in EU

LONDON – Europe's current model of drug development and approval is not appropriate for breakthrough products based on the latest advances in genomics and new understanding of human biology coming up the chain, according to a new report by academic researchers at the Dutch public institute TI Pharma. Read More

TG strategically options global rights to cancer drug from Rhizen

TG Therapeutics Inc., of New York, is exercising an early option to buy exclusive global rights to TGR-1202, a phosphoinositide-3-kinase (PI3K)-delta inhibitor, from its partner, Rhizen Pharmaceuticals SA. Read More

Acute, chronic pain therapy in 'Site' for Janssen Labs spinout

Siteone Therapeutics Inc., incubated at Janssen Labs – Johnson & Johnson's external R&D hub – took a step toward independence by completing its initial equity financing. Read More

Financings

Dermira Inc., of Redwood City, Calif., sets terms for its initial public offering (IPO), upsizing the potential raise, including overallotments, to $98.4 million from its initial filing for $75 million by offering 5.35 million shares priced in a range of $14 to $16. Read More

Stock movers

Read More

Other news to note

Novavax Inc., of Gaithersburg, Md., said the Department of Health and Human Services' Biomedical Advanced Research and Development Authority (BARDA) exercised the option period in its current contract to continue development of the company's recombinant seasonal and pandemic influenza vaccines. Read More

In the clinic

Acceleron Pharma Inc., of Cambridge, Mass., reported interim results from a two-part study sponsored by the Gynecology Oncology Group testing dalantercept as a monotherapy in patients with recurrent or persistent epithelial ovarian cancer. Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for June 11, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for June 11, 2025.
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for June 10, 2025
  • Red blood cells in an artery with cholesterol

    In two phase IIIs, Merck’s PCSK9 inhibitor cuts cholesterol

    BioWorld
    In two phase III studies, Merck & Co. Inc.’s oral, once monthly proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor produced statistically significant...
  • Cancer cell in the cross-hairs

    Pan-cancer proteome atlas reveals new biomarkers and targets

    BioWorld Science
    An international group of scientists has completed the first draft of The Pan-Cancer Proteome Atlas (TPCPA). The project is based on mass spectrometry of 22...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe